Prot #CO39722: A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma

Project: Research project

Project Details

StatusActive
Effective start/end date11/21/171/1/22

Funding

  • Genentech, Inc. (Prot #CO39722)